[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"autosomal-dominant-polycystic-kidney-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:autosomal-dominant-polycystic-kidney-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,70,99,125,150,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100585453","phase-2-anchor-study-a-study-to-assess-the-safety-and-efficacy-of-abbv-cls-628-in-adult-participants-with-autosomal-dominant-polycystic-kidney-disease-adpkd-100585453",false,"NCT06902558","ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)","A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)","ANCHOR","Inclusion Criteria:\n\n* Autosomal Dominant Polycystic Kidney Disease (ADPKD) Class 1C, 1D, or 1E based on the Mayo Clinic Imaging Classification of ADPKD.\n* Estimated glomerular filtration rate (eGFR) \\>= 30 mL\u002Fmin\u002F1.73 m\\^2 and \\\u003C 90 mL\u002Fmin\u002F1.73 m\\^2, using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at Screening.\n\nExclusion Criteria:\n\n* Current interventions to treat ADPKD such as non-approved medications or lifestyle modifications.\n* Any exclusionary medical diseases, disorders, or conditions as described in the protocol.","ALL","18 Years","55 Years",{"count":21,"type":22},240,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that causes fluid-filled cysts to develop in the kidneys. The purpose of this study is to assess the safety and efficacy of ABBV-CLS-628 for the treatment of ADPKD in adult participants.\n\nABBV-CLS-628 is an investigational drug being developed for the treatment of ADPKD. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to placebo. Around 240 adult participants with ADPKD will be enrolled at approximately 100 sites worldwide.\n\nParticipants will receive IntraVenous ABBV-CLS-628 or placebo every 4 weeks for 92 weeks. Participants will be followed for up to 15 weeks.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care . Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.",[28],"Autosomal Dominant Polycystic Kidney Disease",[30,31],"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","ABBV-CLS-628","RECRUITING","2026-05-22",{"date":35,"type":36},"2026-05-26","ACTUAL",{"date":38,"type":36},"2025-06-09",{"date":40,"type":22},"2029-08",{"name":42,"class":43},"Calico Life Sciences LLC","INDUSTRY",75,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100610498","phase-1-safety-tolerability-and-pharmacokinetics-of-azd1613-in-adults-with-autosomal-dominant-polycystic-kidney-disease-100610498","NCT07228364","Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease","A Phase I Randomised, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD1613 Following Multiple Ascending Dose Administration in Participants With Autosomal Dominant Polycystic Kidney Disease","PIONEER-PKD","Inclusion Criteria:\n\n* Patients with ADPKD Mayo Class (IB-IE), as per clinical diagnosis (MIC) assessed centrally. Genetic testing results will not be used for eligibility purposes\n* eGFR = 45 to 90 mL\u002Fmin \u002F1.73m2\n* Body weight ≥ 45 kg and body mass index within the range 18 to 35 kg\u002Fm2 (inclusive).\n* Females are to be of non-childbearing potential\n\nExclusion Criteria:\n\n* As judged by the investigator, any evidence of cardiac, vascular, and other renal conditions which in the investigator's opinion makes it undesirable for the participant to participate in the study.\n* Positive hepatitis C antibody, hepatitis B virus surface antigen, or human immunodeficiency virus test, at screening.\n* History of QT prolongation associated with other medications that required discontinuation of that medication.\n* Congenital long QT syndrome.\n* History of ventricular arrhythmia requiring treatment. Patients with atrial fibrillation\u002Fflutter and controlled ventricular rate HR \\\u003C 100 bpm can be eligible as judged by the investigator.\n* Haemoglobin below the lower limit of the normal range or any other clinically significant haematological abnormality as judged by the investigator.\n* Any clinically important abnormalities in clinical chemistry, haematology, coagulation, or urinalysis results other than those specifically described as exclusion criteria herein, as judged by the investigator.\n* Systolic BP \\> 160 mmHg or diastolic BP \\> 100mmHg or HR \\\u003C 50 bpm or \\> 100 bpm at screening. Patients taking anti-hypertensive medication should be on a stable treatment regimen of antihypertensive therapy for at least 30 days prior to the screening visit.\n* Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG and any abnormalities in the 12-lead ECG that, as considered by the investigator, may interfere with the interpretation of QTc interval changes, including abnormal ST-T-wave morphology or left ventricular hypertrophy.\n* Kidney cyst interventions such as cyst aspiration or cyst fenestration within 12 weeks prior to screening and during the screening period, or such interventions planned or anticipated within the follow-up period.","65 Years",{"count":55,"type":22},40,[57],"PHASE1","A study to investigate safety, tolerability, and pharmacokinetics of AZD1613 following subcutaneous or intravenous administration in participants with autosomal dominant polycystic kidney disease (ADPKD).",[28],"2026-05-08",{"date":62,"type":36},"2026-05-11",{"date":64,"type":36},"2025-11-10",{"date":66,"type":22},"2027-01-26",{"name":68,"class":43},"AstraZeneca",15,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":98},"100434651","phase-3-implementation-of-metformin-therapy-to-ease-decline-of-kidney-function-in-polycystic-kidney-disease-impede-pkd-100434651","NCT04939935","Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)","Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD): A Randomised Placebo-Controlled Trial","Inclusion Criteria:\n\nTo be eligible to participate in this trial, patients must satisfy all of the following inclusion criteria:\n\n1. Willing to participate and provide informed consent\n2. Aged 18-70 years\n3. Diagnosis of ADPKD based on radiological +\u002F- genetic criteria as per Kidney Health Australia - Caring for Australians and New Zealanders with Kidney Impairment (KHA-CARI) Guidelines\n4. eGFR equal to or greater than 38 mL\u002Fmin\u002F1.73m2 and \\\u003C90 mL\u002Fmin\u002F1.73m2\n\nAnd have either:\n\n5(a) One or more risk factors of progression from the following:\n\n* Bilateral kidney length equal to or greater than16.5 cm, or\n* Total Kidney Volume (TKV) equal to or greater than 750 mL or height-adjusted TKV (htTKV) equal to or greater than 600 mL\u002Fm2, or\n* Mayo class IC\u002FD\u002FE or Pro-PKD score equal to or greater than 6 OR 5(b) Evidence of Active progression\n* Decline in eGFR equal to or greater than 5 mL\u002Fmin\u002F1.73m2 in one year, or\n* Decline in eGFR equal to or greater than 3 mL\u002Fmin\u002F1.73m2 per year over five years or more. or\n* Increase in htTKV\u002FTKV of equal to or greater than 5% per year on at least 2 measurements in the past year, excluding any initial eGFR effect over the initial 3 months of tolvaptan commencement (if applicable) Note: Tolvaptan therapy must have been in place for at least 6 months with stable dose for at least 3 months.\n\nExclusion Criteria:\n\n1. Diabetes mellitus (as per American Diabetes Association definition), or other systemic conditions that may cause CKD independent of PKD (excluding hypertension)\n2. Uncontrolled hypertension (Systolic BP \\>160 mmHg and\u002For diastolic BP \\>100 mmHg after a period of rest)\n3. Clinically significant heart failure, including but not limited to New York Heart Association Class (NYHA) III or IV\n4. Non-polycystic liver disease, including but not limited to:\n\n   1. Liver enzymes (ALT, AST or Total Bilirubin) \\>2 times the upper limit of normal, except when a diagnosis of Gilbert Syndrome exists and\u002For,\n   2. Child-Pugh classification score equal to or greater than 5\n5. Any contraindication to metformin including abnormal liver function tests or untreated Vitamin B12 deficiency\n6. Currently taking metformin\n7. Pregnancy or breastfeeding, or planning to get pregnant in the next three years.\n8. Comorbidities with potential to contaminate trial outcomes, specifically active cancer, history of other solid organ transplantations, active chronic obstructive pulmonary disease (COPD), active inflammatory bowel disease, and the presence of stoma.\n9. History of dialysis.","70 Years",{"count":79,"type":22},1174,[81],"PHASE3","This study will investigate if a medication (metformin) widely used in the treatment of diabetes could be re-purposed for the treatment of patients with a diagnosis of early stage ADPKD to slow the rate of kidney function decline, reducing morbidity and mortality and improving the quality of life for ADPKD patients.",[28],[85,86,87],"Placebo","Metformin","ADPKD","2026-03-26",{"date":90,"type":36},"2026-03-31",{"date":92,"type":36},"2022-11-29",{"date":94,"type":22},"2030-12",{"name":96,"class":97},"The University of Queensland","OTHER",49,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":105,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100388969","characterization-of-the-nrf2-response-in-patients-with-autosomal-dominant-polycystic-kidney-disease-adpkd-100388969","NCT04344769","Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Inclusion Criteria (ADPKD Subjects):\n\n* ADPKD (based on Ravine et al. criteria)\n* Class 1 B-E according to our imaging classification\n* Male and female subjects 18 - 30 years of age, inclusive\n* Estimated GFR\\> 60 mL\u002Fmin\u002Fm2 (CKD-EPI equation)\n* Ability to provide written, informed consent.\n\nExclusion Criteria (ADPKD Subjects):\n\n* Class 2 according to our imaging classification\n* Concomitant systemic disease in the kidney (e.g. lupus, hepatitis B or C, amyloidosis)\n* Diabetes mellitus (fasting glucose \\> 126 mg\u002FdL or treatment with insulin or oral hypoglycemics).\n* Predicted urine protein excretion in urinalysis \\>1 g\u002F24 hrs\n* Abnormal urinalysis suggestive of concomitant glomerular disease.\n* Subjects having contraindications to, or interference with MRI assessments. \\[For example: ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal\u002Fback tattoos, etc\\].\n* Female subjects that are pregnant\n\nInclusion Criteria (Healthy Subjects):\n\n* Male and female subjects 18 - 30 years of age, inclusive\n* Estimated GFR\\> 60 mL\u002Fmin\u002Fm2 (CKD-EPI equation)\n* Ability to provide written, informed consent.\n\nExclusion Criteria (Healthy Subjects):\n\n* Previous personal or family history of kidney disease.\n* Concomitant systemic disease in the kidney (e.g. lupus, hepatitis B or C, amyloidosis)\n* Diabetes mellitus (fasting glucose \\> 126 mg\u002FdL or treatment with insulin or oral hypoglycemics).\n* Presence of proteinuria\n* Abnormal urinalysis suggestive glomerular disease.\n* Subjects having contraindications to, or interference with MRI assessments. \\[For example: ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal\u002Fback tattoos, etc\\]\n* Female subjects that are pregnant",true,"30 Years",{"count":55,"type":22},"OBSERVATIONAL","The purpose of this study is to characterize oxidative stress and the Nrf2 antioxidant response in early stages of Autosomal Dominant Polycystic Kidney Disease (ADPKD), while identifying candidate biomarkers.",[28],[112,113,114,87],"Oxidative Stress","Antioxidant Response","Nrf2","2026-01-15",{"date":117,"type":36},"2026-01-16",{"date":119,"type":36},"2019-10-04",{"date":121,"type":22},"2026-12",{"name":123,"class":97},"Mayo Clinic",1,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":132,"maxAge":133,"enrollmentInfo":134,"targetDuration":136,"studyType":108,"phases":4,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":124},"100410907","nox4-and-related-biomarkers-in-adpkd-100410907","NCT04630613","NOX4 and Related Biomarkers in ADPKD","NOX4, Mitochondria and Related Biomarkers in Autosomal Dominant Polycystic Kidney Disease","Inclusion Criteria:\n\n* ADPKD (based on Ravine et al. criteria)\n* Class 1 A-E according to imaging classification\n* Male and female subjects 15 - 40 years of age\n* Estimated GFR\\> 70 mL\u002Fmin\u002F1.73 m2 (CKD-EPI)\n* Ability to provide written, informed consent\n\nExclusion Criteria:\n\n* Class 2 according to imaging classification\n* Concomitant systemic disease affecting the kidney\n* Diabetes mellitus\n* Predicted urine protein excretion in \\>1 g\u002F24 hrs\n* Use of antioxidants i.e. vitamins, Nrf2 activators\n* Abnormal urinalysis","15 Years","40 Years",{"count":135,"type":22},60,"2 Years","To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).",[28],[112,140,141],"Mitochondria injury and function","NADPH oxidase 4","2026-01-07",{"date":144,"type":36},"2026-01-09",{"date":146,"type":36},"2020-07-21",{"date":148,"type":22},"2027-01",{"name":123,"class":97},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":159,"briefSummary":160,"conditions":161,"keywords":162,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":176},"100549579","phase-2-short-term-effects-of-an-sglt2-inhibitor-on-divalent-ions-in-autosomal-dominant-polycystic-kidney-disease-100549579","NCT06435858","Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease","SIDIA","Inclusion Criteria:\n\n* \\- Patients 18-75 years old with ADPKD, defined according to international diagnostic and classification criteria14, treated at Cantonal Hospital Graubünden (KSGR) and the University Hospital Zürich (USZ) independent of baseline treatment with the vasopressin receptor antagonist Tolvaptan\n* Informed consent as documented by signature\n\nExclusion Criteria:\n\n* \\- renal replacement therapy or kidney allograft recipient\n* chronic kidney disease CKD KDIGO Stage G4 (eGFR under 30ml\u002Fmin\u002F1.73m2)\n* patients younger 18 years of age\n* Diabetes mellitus type 1\n* recurrent urinary tract infections (UTI) defined as more than 3 infections requiring antibiotic treatment or over 1 requiring hospitalization\u002Fyear.\n* Patients with uncontrolled hypertension (defined as ambulatory systolic BP over 180mmHg), liver cirrhosis (Child Pugh B and C)\n* Patients not able or not willing to stop the following medications during the study period of participation in the trial:\n* Thiazide diuretics\n* Carbonic anhydrase inhibitors\n* Sodium bicarbonate\n* 1, 25 (OH) vitamin D (calcitriol)\n* Bisphosphonate, denosumab, teriparatide\n* Pregnant or lactating women\n* Known allergy to study drug\n* Inability to understand and follow the protocol","75 Years",{"count":55,"type":22},[25],"This study aims to better understand electrolyte handling in patients with autosomal dominant polycystic kidney disease treated with the SGLT2 inhibitor Empagliflozin.\n\nPatients will be randomized into two groups and take Empagliflozin or a Placebo for 2 weeks with a wash-out period of 2 weeks. The primary outcome is tubular handling of the divalent ions calcium, phosphate and magnesium. Secondary outcomes include diuresis, safety and tolerability.",[28],[163,164,165,166,87],"phosphate","calcium","magnesium","Empagliflozin","2025-09-08",{"date":169,"type":36},"2025-09-12",{"date":171,"type":36},"2024-09-01",{"date":173,"type":22},"2025-10",{"name":175,"class":97},"Cantonal Hospital Graubuenden",2,{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":185,"targetDuration":106,"studyType":108,"phases":4,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":124},"100521150","national-registry-of-rare-kidney-diseases-100521150","NCT06065852","National Registry of Rare Kidney Diseases","National Registry of Rare Kidney Diseases (RaDaR)","RaDaR","* Kidney Rare Disease\n* Paeds and adults\n* Eligibility differs for each rare disease group\n* See: https:\u002F\u002Fukkidney.org\u002Frare-renal\u002Frecruitment",{"count":186,"type":22},35000,"The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.\n\nThe purpose of this research is to:\n\n* Develop Clinical Guidelines for specific rare kidney diseases. These are written recommendations on how to diagnose and treat a medical condition.\n* Audit treatments and outcomes. An audit makes checks to see if what should be done is being done and asks if it could be done better.\n* Further the development of future treatments.\n\nParticipants will be invited to participate on clinical trials and other studies. The registry has the capacity to feedback relevant information to patients and in conjunction with Patient Knows Best (Home - Patients Know Best), allows patients to provide information themselves, including their own reported quality of life and outcome measures.",[189,190,191,192,193,194,195,196,197,28,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271],"Adenine Phosphoribosyltransferase Deficiency","AH Amyloidosis","AHL Amyloidosis","AL Amyloidosis","Alport Syndrome","Atypical Hemolytic Uremic Syndrome","Autoimmune Distal Renal Tubular Acidosis","Autosomal Recessive Proximal Renal Tubular Acidosis","Autosomal Recessive Distal Renal Tubular Acidosis","Autosomal Recessive Polycystic Kidney Disease","Bartter Syndrome","BK Nephropathy","C3 Glomerulopathy With Monoclonal Gammopathy","C3 Glomerulopathy","Calciphylaxis","Crystalglobulinaemia","Crystal-storing Histiocytosis","Cystinosis","Cystinuria","Dense Deposit Disease","Dent Disease","Denys-Drash Syndrome","Dominant Hypophosphataemia With Nephrolithiasis and\u002For Osteoporosis","Drug Induced Fanconi Syndrome","Drug-Induced Hypomagnesemia","Drug-Induced Nephrogenic Diabetes Insipidus","Epilepsy, Ataxia, Sensorineural Deafness and Tubulopathy","Fabry Disease","Familial Hypomagnesemia With Hypercalciuria and Nephrocalcinosis","Familial Primary Hypomagnesemia With Hypocalcuria","Familial Primary Hypomagnesaemia With Normocalciuria","Familial Renal Glucosuria","Fanconi Renotubular Syndrome 1","Fanconi Renotubular Syndrome 2","Fanconi Renotubular Syndrome 3","Fibrillary Glomerulonephritis","Fibromuscular Dysplasia","Focal Segmental Glomerulosclerosis","Generalised Pseudohypoaldosteronism Type 1","Gitelman Syndrome","Heavy-Metal-Induced Fanconi Syndrome","Hepatocyte Nuclear Factor 1-Beta-Associated Monogenic Diabetes","Hereditary Renal Hypouricemia","Hereditary Hypophosphatemic Rickets With Hypercalciuria","Hyperuricaemic Nephropathy","IgA Nephropathy","Immunotactoid Glomerulonephritis With Organised Microtubular Mononoclonal Immunoglobulin Deposits","Inherited Renal Cancer Syndromes","Intracapillary Monoclonal IgM Without Cryoglobulin","Intraglomerular\u002FCapillary Lymphoma\u002FLeukaemia","Isolated Autosomal Dominant Hypomagnesaemia Glaudemans Type","Liddle Syndrome","Light Chain Cast Nephropathy","Light Chain Proximal Tubulopathy Without Crystals","Light Chain Proximal Tubulopathy With Crystals","Lowe Syndrome","Membranous Nephropathy","Membranoproliferative Glomerulonephritis","Medullary Cystic Kidney Disease","Minimal Change Nephropathy","Mitochondrial Disease Of The Kidney","Monoclonal Immunoglobulin Deposition Disease","Nail Patella Syndrome","Nephrogenic Diabetes Insipidus","Nephrogenic Syndrome of Inappropriate Antidiuresis","Nephronophthisis","Primary Hypomagnesemia With Secondary Hypocalcemia","Primary Hyperoxaluria","Proliferative Glomerulonephritis With Monoclonal IgG Deposits","Proximal Tubulopathy Without Crystals","Pseudohypoaldosteronism Type 1, 2A-2E","Pure Red Cell Aplasia","Retroperitoneal Fibrosis","Sickle Cell Nephropathy","Shiga Toxin Associated Haemolytic Uraemic Syndrome","Steroid Resistant Nephrotic Syndrome","Steroid-Sensitive Nephrotic Syndrome","Thin Basement Membrane Nephropathy","Thrombotic Microangiopathy With Monoclonal Gammopathy","Type 1 Cryoglobulinaemic Glomerulonephritis","Tuberous Sclerosis","Unclassified Monoclonal Gammopathy Of Renal Significance","Vasculitis","2023-09-26",{"date":274,"type":36},"2023-10-04",{"date":276,"type":36},"2009-11-06",{"date":278,"type":22},"2039-12-31",{"name":280,"class":97},"UK Kidney Association"]